A Prospective, Randomized, Open Label, Single-Centre Study for Assessment of Safety and Effectiveness of Recombinant Human Insulin 30/70 + Insulin Glulisine compared to Recombinant Human Insulin NPH + Regular in the Management of Type 2 Diabetes Mellitus Patients in the Philippines.


Background The high prevalence of type 2 diabetes mellitus (T2DM) in Philippines has burdened the health care system. Therefore, we compared standard of care, Insulin30/70+ Insulin Glulisine (Arm B) to a traditional insulin regimen NPH Insulin+Regular Insulin (Arm A) to test the concept that both provide comparable efficacy and safety in real world practice.

Methods This is a ‘proof-of-concept’, prospective, randomized, open label study of 40 consecutive Filipino T2DM participants from October 2015 to June 2016. The primary endpoint was reduction in HbA1c at 12 weeks. The secondary endpoints were changes in Fasting Plasma Glucose (FPG), Post Prandial Glucose (PPG), Capillary Blood Sugar (CBS), weight and insulin dose at 12 weeks. ANCOVA and Fisher’s exact tests were used.

Results Treatment arm A reported comparable glycemic control to arm B as measured by reductions in HbA1c (2.89% vs. 2.67%; P = 0.657), FPG (65.94 vs. 46.71 mg/ dl; P = 0.57), PPG (76.49 vs. 86.96 mg/ dl; P = 0.271) and CBS (115.15 vs. 145.95 mg/ dl; P = 0.420). Both treatment arms reported similar weight gain (1.92 vs. 1.22 kg), experienced similar incidence of hypoglycemia (7 vs. 6 patients) and adverse events (8 vs. 8 patients).


Traditional combination of NPH Insulin + Regular Insulin offers comparable glycemic control and tolerance as the standard of care without any new safety signals in Filipino T2DM population. With a lower price, it can be one of the strategies to reduce financial burden of antidiabetic treatment.

  1. World Health Organization. Diabetes Action Now: An initiative of the World Health Organization and the International Diabetes Federation. 2004. Available from: https://apps.who.int/iris/bitstream/handle/10665/42934/924159151X.pdf?sequence=1&isAllowed=y
  2. Chuang LM, Tsai ST, Huang BY, Tai TY. The status of diabetes control in Asia—a cross‐sectional survey of 24 317 patients with diabetes mellitus in 1998. Diabetic Medicine. 2002 Dec;19(12):978–85.
  3. International Diabetes Federation. Diabetes Atlas. 3rd ed. Brussels, Belgium; 2006. Available from: Diabetes-Atlas-3rd-edition.pdf
  4. Balkau B. The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes & Metabolism. 2000 Sep; 26(4):282–6.
  5. Hanefeld M, Temelkova-Kurktschiev T. Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD. 2002 Apr;12(2):98–107.
  6. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of Internal Medicine. 2003 Jun 9;163(11):1306–16.
  7. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, et al. Postprandial glucose regulation and diabetic complications. Archives of Internal Medicine. 2004 Oct 25;164(19):2090–5.
  8. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003 May 7;289(17):2254–64.
  9. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Annals of Internal Medicine. 2006 Jul 18;145(2):125–34.
  10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan 1;32(1):193–203.
  11. Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes. 2005 Apr 1; 23(2):78–86.
  12. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005 May 1;28(5):1245–9.
  13. Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Advanced Drug Delivery Reviews. 1999 Feb 1;35(2-3):307–35.
  14. Reynolds LR, Karounos DG. Emerging technology in diabetes mellitus: glucose monitoring and new insulins. Southern Medical Journal. 2002 Aug 1;95(8):914–9.
  15. Palmer JL, Knudsen MS, Aagren M, Thomsen TL. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. Journal of Medical Economics. 2010 Jul 14;13(2):212–20.
  16. American Diabetes Association. Standards of medical care in diabetes —2007. Diabetes Care. 2007;30(Suppl. 1):S4–S41.
  17. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D,  et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. The Lancet. 2008 May 24;371(9626):1753–60.
  18. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008 Oct 1;31(10):1927–32.
  19. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. The Lancet. 2008 May 24;371(9626):1725–6.
  20. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 2004 Nov 1;27(11):2597–602.
  21. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997 Sep 1;20(9):1353–6.
  22. Park S, Choi SB. Induction of long‐term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes/Metabolism Research and Reviews. 2003 Mar;19(2):124–30.
  23. Davidson JA, Einhorn D, Allweiss P, Flood, Face TM, Garber AJ, Garcia MJ, Kahn CB, Soler NG, White Jr. JR, Huster WJ. Effect of premixed nph and regular insulin on glucose control and health-related quality of life in patients with type 2 diabetes mellitus. Endocrine Practice. 1997 Nov 1;3(6):331–6.
  24. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA. 1998 Jul 8;280(2):140–6.
  25. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995;18:1415–27.
  26. US Food and Drug Administration. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Rockville: US Food and Drug Administration. 2008 Feb. Available from: http://fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm071627.pdf
  27. Leiter LA, Yale JF, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29(3):186–92.
  28. Brunton SA. Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. Medscape General Medicine. 2007;9(2):38.
  29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998 Sep 12;352(9131):837–53.
  30. Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME, Kharazmi E, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PloS One. 2011 Oct 31;6(10):e26864.
  31. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013 Apr 1;36(4):1033–46.

Articles related to the one you are viewing

There are currently no results to show, please try again later

CC BY: Open Access Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/